ZA200301636B - Fermentation process for the preparation of L-threonine. - Google Patents
Fermentation process for the preparation of L-threonine. Download PDFInfo
- Publication number
- ZA200301636B ZA200301636B ZA200301636A ZA200301636A ZA200301636B ZA 200301636 B ZA200301636 B ZA 200301636B ZA 200301636 A ZA200301636 A ZA 200301636A ZA 200301636 A ZA200301636 A ZA 200301636A ZA 200301636 B ZA200301636 B ZA 200301636B
- Authority
- ZA
- South Africa
- Prior art keywords
- threonine
- resistance
- fermentation
- process according
- producing
- Prior art date
Links
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 title claims description 142
- 238000000855 fermentation Methods 0.000 title claims description 88
- 230000004151 fermentation Effects 0.000 title claims description 88
- 239000004473 Threonine Substances 0.000 title claims description 72
- 229960002898 threonine Drugs 0.000 title claims description 72
- 238000002360 preparation method Methods 0.000 title claims description 15
- 241000588724 Escherichia coli Species 0.000 claims description 47
- 229930006000 Sucrose Natural products 0.000 claims description 36
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 36
- 239000005720 sucrose Substances 0.000 claims description 36
- 235000010633 broth Nutrition 0.000 claims description 32
- 239000001963 growth medium Substances 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 30
- 244000005700 microbiome Species 0.000 claims description 26
- 230000008569 process Effects 0.000 claims description 26
- 230000002238 attenuated effect Effects 0.000 claims description 15
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 13
- 108010055400 Aspartate kinase Proteins 0.000 claims description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- 241000588921 Enterobacteriaceae Species 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 101710088194 Dehydrogenase Proteins 0.000 claims description 9
- 108010006873 Threonine Dehydratase Proteins 0.000 claims description 9
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 8
- 108010043075 L-threonine 3-dehydrogenase Proteins 0.000 claims description 7
- OJCKRNPLOZHAOU-RSXXJMTFSA-N (1r,2r)-2-[(2s,4e,6e,8r,9s,11r,13s,15s,16s)-7-cyano-8,16-dihydroxy-9,11,13,15-tetramethyl-18-oxo-1-oxacyclooctadeca-4,6-dien-2-yl]cyclopentane-1-carboxylic acid Chemical compound O1C(=O)C[C@H](O)[C@@H](C)C[C@@H](C)C[C@@H](C)C[C@H](C)[C@@H](O)\C(C#N)=C\C=C\C[C@H]1[C@H]1[C@H](C(O)=O)CCC1 OJCKRNPLOZHAOU-RSXXJMTFSA-N 0.000 claims description 5
- OJCKRNPLOZHAOU-BNXNOGCYSA-N Borrelidin Natural products CC1CC(C)CC(C)C(O)C(=C/C=C/CC(OC(=O)CC(O)C(C)C1)C2CCCC2C(=O)O)C#N OJCKRNPLOZHAOU-BNXNOGCYSA-N 0.000 claims description 5
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 5
- 229930195722 L-methionine Natural products 0.000 claims description 5
- 229960004452 methionine Drugs 0.000 claims description 5
- PGNYNCTUBKSHHL-UHFFFAOYSA-N 2,3-diaminobutanedioic acid Chemical compound OC(=O)C(N)C(N)C(O)=O PGNYNCTUBKSHHL-UHFFFAOYSA-N 0.000 claims description 4
- CDUUKBXTEOFITR-UHFFFAOYSA-N 2-methylserine zwitterion Chemical compound OCC([NH3+])(C)C([O-])=O CDUUKBXTEOFITR-UHFFFAOYSA-N 0.000 claims description 4
- CXABZTLXNODUTD-UHFFFAOYSA-N 3-fluoropyruvic acid Chemical compound OC(=O)C(=O)CF CXABZTLXNODUTD-UHFFFAOYSA-N 0.000 claims description 4
- 108010064711 Homoserine dehydrogenase Proteins 0.000 claims description 4
- 229960002989 glutamic acid Drugs 0.000 claims description 4
- 101150048892 parB gene Proteins 0.000 claims description 4
- 230000035945 sensitivity Effects 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- 229930182844 L-isoleucine Natural products 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- 230000003698 anagen phase Effects 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims description 2
- 230000003248 secreting effect Effects 0.000 claims 7
- 239000002609 medium Substances 0.000 description 32
- 229910052760 oxygen Inorganic materials 0.000 description 29
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 28
- 239000001301 oxygen Substances 0.000 description 28
- 239000000203 mixture Substances 0.000 description 25
- 235000015097 nutrients Nutrition 0.000 description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 16
- 239000008103 glucose Substances 0.000 description 16
- 239000000470 constituent Substances 0.000 description 15
- 239000013587 production medium Substances 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 238000005273 aeration Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- 238000011081 inoculation Methods 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 235000000346 sugar Nutrition 0.000 description 10
- 229940041514 candida albicans extract Drugs 0.000 description 9
- 239000012138 yeast extract Substances 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 8
- 229960000723 ampicillin Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 241001646716 Escherichia coli K-12 Species 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 241000607715 Serratia marcescens Species 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 5
- 239000002054 inoculum Substances 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108700028369 Alleles Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000012527 feed solution Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000005086 pumping Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 3
- 241000588722 Escherichia Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 241000607720 Serratia Species 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- -1 for example Chemical class 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000013379 molasses Nutrition 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 239000006142 Luria-Bertani Agar Substances 0.000 description 2
- BVIAOQMSVZHOJM-UHFFFAOYSA-N N(6),N(6)-dimethyladenine Chemical compound CN(C)C1=NC=NC2=C1N=CN2 BVIAOQMSVZHOJM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 229960004295 valine Drugs 0.000 description 2
- GMKMEZVLHJARHF-UHFFFAOYSA-N (2R,6R)-form-2.6-Diaminoheptanedioic acid Natural products OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 101100278012 Escherichia coli (strain K12) dnaG gene Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000408495 Iton Species 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- GGLZPLKKBSSKCX-YFKPBYRVSA-N L-ethionine Chemical compound CCSCC[C@H](N)C(O)=O GGLZPLKKBSSKCX-YFKPBYRVSA-N 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000364057 Peoria Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 108091000041 Phosphoenolpyruvate Carboxylase Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000588768 Providencia Species 0.000 description 1
- 108010053763 Pyruvate Carboxylase Proteins 0.000 description 1
- 102100039895 Pyruvate carboxylase, mitochondrial Human genes 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 101100165173 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) basS gene Proteins 0.000 description 1
- 101100421924 Thermus thermophilus (strain ATCC BAA-163 / DSM 7039 / HB27) spo0C gene Proteins 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 102000006843 Threonine synthase Human genes 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102100033451 Thyroid hormone receptor beta Human genes 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000019728 animal nutrition Nutrition 0.000 description 1
- 229940045686 antimetabolites antineoplastic purine analogs Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- JGGLZQUGOKVDGS-VYTIMWRQSA-N aspartate semialdehyde Chemical compound O[C@@H]1[C@@H](NC(=O)C)CO[C@H](CO)[C@H]1O[C@@H]1[C@@H](NC(C)=O)[C@H](O)[C@H](O[C@@H]2[C@H]([C@@H](O[C@@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](CO)O3)O[C@@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](CO)O3)O[C@@H]3[C@H]([C@H](O)[C@@H](O)[C@H](CO)O3)O)[C@@H](O)[C@H](CO[C@@H]3[C@H]([C@H](O[C@@H]4[C@H]([C@H](O)[C@@H](O)[C@H](CO)O4)O)[C@@H](O)[C@H](CO)O3)O)O2)O)[C@H](CO)O1 JGGLZQUGOKVDGS-VYTIMWRQSA-N 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 101150004979 flmA gene Proteins 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 108010071598 homoserine kinase Proteins 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- GMKMEZVLHJARHF-SYDPRGILSA-N meso-2,6-diaminopimelic acid Chemical compound [O-]C(=O)[C@@H]([NH3+])CCC[C@@H]([NH3+])C([O-])=O GMKMEZVLHJARHF-SYDPRGILSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229940066779 peptones Drugs 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920001522 polyglycol ester Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- GHSJKUNUIHUPDF-UHFFFAOYSA-N s-(2-aminoethyl)-l-cysteine Chemical compound NCCSCC(N)C(O)=O GHSJKUNUIHUPDF-UHFFFAOYSA-N 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 150000003680 valines Chemical class 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 108010062110 water dikinase pyruvate Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/08—Lysine; Diaminopimelic acid; Threonine; Valine
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
« wy - 1
Fermentation Process for the Preparation of L-~Threonine . Field of the Invention
The invention provides a new process for the fermentative preparation of L-threonine with Enterobacteriaceae.
Prior Art
L-Threonine is used in animal nutrition, in human medicine and in the pharmaceuticals industry.
It is known that L-threonine can be prepared by fermentation of strains of the Enterobacteriaceae family, in particular Escherichia coli. Because of the great : importance of this amino acid, work is constantly being undertaken to improve the preparation processes.
Improvements to the process can relate to fermentation measures, such as e.g. stirring and supply of oxygen, or the composition of the nutrient media, such as e.g. the sugar concentration during the fermentation, or the working up to the product form, by e.g. ion exchange chromatography, or the intrinsic output properties, i.e. those of genetic origin, of the microorganism itself.
It is known from the prior art, such as is described, for example, in US-A-5,538,873 and in EP-B-0593792 or by
Okamoto et al. (Bioscience, Biotechnology, and Biochemistry 61 (11), 1877 - 1882, 1997), that threonine is prepared by fermentation in the batch process (batch) or feed process (fed batch).
Object of the Invention ‘The inventors had the object of providing new measures for } improved fermentative preparation of L-threonine.
wy
Y
- 2
Summary of the Invention , The invention provides a fermentation process, which is characterized in that a) an L-threonine-producing microorganism of the
Enterobacteriaceae family is cultured by the feed process (fed batch) in a known manner, subsequently b) a portion of the fermentation broth is separated off, 1 to 90 vol.%, in particular 1 to 50 vol.%, preferably 1 to 25 vol.% and particularly preferably 5 to 50 vol.$ of the total volume of the fermentation broth remaining in the fermentation tank, subsequently c) the remaining fermentation broth is topped up with growth medium and, preferably after a growth phase, a further fermentation is carried out by the feed process (fed batch) mentioned, d) steps b) and c) are optionally carried out several times, and e) the L-threonine is isolated from the fermentation broths collected.
The microorganisms with which the process according to the invention can be carried out can prepare L-threonine from glucose, sucrose, lactose, fructose, maltose, molasses, starch, or from glycerol and ethanol, the preparation from glucose, sucrose or molasses being preferred. They are representatives of Enterobacteriaceae, in particular of the ) genera Escherichia, Serratia and Providencia. Of the genus
Escherichia the species Escherichia coli and of the genus
Serratia the species Serratia marcescens are to be mentioned in particular.
i WO 02/18543 PCT/EP01/08603
Suitable L-threonine-producing strains of the genus
Escherichia, in particular of the species Escherichia coli, : are, for example . Escherichia coli TF427
Escherichia coli H-4225
Escherichia coli H-4226
Escherichia coli H-4257
Escherichia coli H-4258
Escherichia coli H-4435
Escherichia coli H-4436
Escherichia coli H-4578
Escherichia coli H-7256
Escherichia coli H-7263
Escherichia coli H-7293
Escherichia coli H-7294
Escherichia coli H-7700 ’
Escherichia coli H-7729
Escherichia coli H-8309 : Escherichia coli H-8311
Escherichia coli H-9244
Escherichia coli KY10935
Escherichia coli EL1003
Escherichia coli VNIIgenetika MG-442
Escherichia coli VNIIgenetika VL334/pYN7
Escherichia coli VNIIgenetika M1
Escherichia coli VNIIgenetika 472T23
Escherichia coli VNIIgenetika TDH-6
Escherichia coli BKIIM B-3996
Escherichia coli BKIIM B-5318
Escherichia coli B-3996-C43 . Escherichia coli B-3996-C80
Escherichia coli B-3996/pTWV-pps , Escherichia coli B-3996 (pMW: : THY)
Escherichia coli B-3996/pBP5
Escherichia coli Ferm BP-3756
Escherichia coli Ferm BP-4072 i WO 02/18543 PCT/EP01/08603 v 4
Escherichia coli Ferm BP-1411
Escherichia coli kat 13 ~ Escherichia coli KCCM-10132
Escherichia coli KCCM-10133. 5S Suitable L-threonine-producing strains of the genus
Serratia, in particular of the species Serratia marcescens, are, for example
Serratia marcescens HNr21l
Serratia marcescens TLrl56
Serratia marcescens T2000
Strains from the Enterobacteriaceae family which produce L- threonine preferably have, inter alia, one or more genetic or phenotypic features chosen from the group consisting of: resistance to a-amino-f-hydroxyvaleric acid, resistance to thialysine, resistance to ethionine, resistance to a- methylserine, resistance to diaminosuccinic acid, resistance to a-aminobutyric acid, resistance to borrelidin, resistance to rifampicin, resistance to valine analogues, such as, for example, valine hydroxamate, resistance to purine analogues, such as, for example, 6- dimethylaminopurine, a need for L-methionine, optionally a partial and compensatable need for L-isoleucine, a need for meso-diaminopimelic acid, auxotrophy in respect of threonine-containing dipeptides, resistance to L-threonine, resistance to L-homoserine, resistance to L-lysine, resistance to L-methionine, resistance to L-glutamic acid, resistance to L-aspartate, resistance to L-leucine, resistance to L-phenylalanine, resistance to L-serine, resistance to L-cysteine, resistance to L-valine, ’ 30 sensitivity to fluoropyruvate, defective threonine dehydrogenase, optionally an ability for sucrose : utilization, enhancement of the threonine operon, enhancement of homoserine dehydrogenase I-aspartate kinase
I, preferably of the feed back resistant form, enhancement of homoserine kinase, enhancement of threonine synthase,
v 5 enhancement of aspartate kinase, optionally of the feed back resistant form, enhancement of aspartate semialdehyde } dehydrogenase, enhancement of phosphoenol pyruvate carboxylase, optionally of the feed back resistant form, i 5 enhancement of phosphoenol pyruvate synthase, enhancement of transhydrogenase, enhancement of the RhtB gene product, enhancement of the RhtC gene product, enhancement of the
YfiK gene product, enhancement of a pyruvate carboxylase, and attenuation of acetic acid formation.
Thus, for example, the strain 472T23 (US-A-5,631,157) has, inter alia, an enhanced, "feed back" resistant aspartate kinase I-homoserine dehydrogenase I, an attenuated threonine deaminase, a resistance to at least 5 g/1 L- threonine and the ability to utilize sucrose as a source of carbon.
Thus, for example, the strain B-3996 (US-A-5,175,107) has, inter alia, an enhanced, "feed back" resistant aspartate kinase I-homoserine dehydrogenase I, an attenuated threonine deaminase, an attenuated threonine dehydrogenase, a resistance to at least 5 g/l L-threonine and the ability to utilize sucrose as a source of carbon.
Thus, for example, the strain kat-13 (US-A-5,939,307) has, inter alia, an enhanced, "feed back" resistant aspartate kinase I-homoserine dehydrogenase I, an attenuated : threonine dehydrogenase, resistance to borrelidin and the ability to utilize sucrose as a source of carbon.
Thus, for example, the strain KCCM-10132 (WO 00/09660) has a resistance to a-methylserine, a resistance to . diaminosuccinic acid, sensitivity to fluoropyruvate, a resistance to L-glutamic acid and a resistance to at least 7% L-threonine. The strain is also in need of the amino acids L-methionine and L-isoleucine.
The term "enhancement" in this connection describes the increase in the intracellular activity of one or more ) enzymes in a microorganism which are coded by the corresponding DNA, for example by increasing the number of ' 5 copies of the gene or allele or of the genes or alleles, using a potent promoter or using a gene or allele which codes for a corresponding enzyme having a high activity, and optionally combining these measures.
By enhancement measures, in particular over-expression, the activity or concentration of the corresponding protein is in general increased by at least 10%, 25%, 50%, 75%, 100%, 150%, 200%, 300%, 400% or 500%, up to a maximum of 1000% or 2000%, based on the starting microorganism.
The term "attenuation" in this connection describes the reduction or elimination of the intracellular activity of one or more enzymes (proteins) in a microorganism which are coded by the corresponding DNA, for example by using a weak promoter or using a gene or allele which codes for a corresponding enzyme with a low activity or inactivates the corresponding gene or enzyme (protein), and optionally combining these measures.
By attenuation measures, the activity or concentration of the corresponding protein is in general reduced to 0 to 50%, 0 to 25%, 0 to 10% or 0 to 5% of the activity or concentration of the wild-type protein.
According to the invention, the system output of a fermentation unit producing L-threonine is increased by a procedure in which after a first fermentation step a . portion of the fermentation broth obtained in this way remains in the production fermenter and serves as the inoculum for one or more further fermentation steps (batches).
According to the invention, 1 to 90 vol.%, preferably 1 to 50 vol.%, preferentially 1 to 25 vol.%, 1 to 20 vol.%, 1 to ’ 15 vol.% or 1 to 10 vol.%, and particularly preferably 5 to 20 vol.%, 5 to 15 vol.% or 1 to 10 vol.% of the total ‘ 5 volume of the fermentation broth remains in the fermentation tank.
The broth remaining in the fermentation tank is preferably topped up with a growth medium. After optionally > 0 to not more than 10 hours, preferably after 1 to 10 hours, preferentially 2 to 10 hours and particularly preferably 3 to 7 hours a production medium is fed in. Alternatively, the components of this medium can also be fed in separately. After 20 to 72 hours, preferably 20 to 48 hours, the batch is ended and a portion of the fermentation broth, as described above, is separated off. A new fermentation stage is then optionally started with the remainder. The process can be repeated at least once, preferably approx. 2 to 6 times, depending on the stability of the strain used. Repetitions of approx. 2 to 8 times or 200 2 to 10 times or 2 to 4 times are also possible.
Appropriately stable strains which do not lose their production properties in the course of the process are particularly suitable for the process described.
The growth medium typically comprises sugars, such as e.g. glucose, starch hydrolysate, sucrose or molasses, as the source of carbon. Organic nitrogen-containing compounds, such as peptones, yeast extract, meat extract, malt extract, corn steep liquor, soya bean flour and urea, or inorganic compounds, such as ammonium sulfate, ammonium ) 30 chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate, can be used as the source of nitrogen. ’ The sources of nitrogen can be used individually or as a mixture. Phosphoric acid, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium- containing salts can be used as the source of phosphorus.
v 8
The culture medium must furthermore comprise salts of metals, such as e.g. magnesium sulfate, manganese sulfate : or iron sulfate, which are necessary for growth. Finally, essential growth substances, such as amino acids (e.g. ‘ 5 homoserine) and vitamins (e.g. thiamine), are employed in addition to the above-mentioned substances. Antifoams, such as e.g. fatty acid polyglycol esters, can be employed to control the development of foam.
In general, the production medium comprises only one sugar, such as e.g. sucrose or glucose, and optionally an inorganic source of nitrogen, such as e.g. ammonium sulfate. Alternatively, these and other components can also be fed in separately.
During the growth or production phase, the temperature is established in a range from 29°C to 42°C, preferably 33°C to 40°C. Temperatures in a range from 27°C to 39°C are also possible. The fermentation can be carried out under normal pressure or optionally under increased pressure, preferably under an increased pressure of 0 to 1.5 bar. The oxygen partial pressure is regulated at 5 to 50%, preferably approx. 20% atmospheric saturation. Regulation of the pH to a pH of approx. 6 to 8, preferably 6.5 to 7.5, can be effected with 25% aqueous ammonia.
The process according to the invention is distinguished with respect to conventional processes above all by an increased space/time yield or productivity.
The present invention is explained in more detail in the following with the aid of embodiment examples.
The isolation of plasmid DNA from Escherichia coli and all techniques of restriction, Klenow and alkaline phosphatase treatment were carried out by the method of Sambrook et al. (Molecular Cloning. A laboratory manual (1989) Cold Spring
Harbor Laboratory Press). Unless described otherwise, the transformation of Escherichia coli was carried out by the method of Chung et al. (Proceedings of the National Academy ) of Sciences of the United States of America USA (1989) 86: 2172-2175). 5S Example 1
Preparation of the Escherichia coli K-12 strain DM1265
A plasmid-free variant of the E. coli strain 472T23 was obtained from the American Type Culture Collection (Manasas, VA., USA) as ATCC98082. The strain ATCC98082 is described in the patent specification US-A-5,631,157. The
E. coli strain VL334/pYN7 was obtained from the Russian
National Collection of Industrial Microorganisms (VKPM,
Moscow, Russia) as CMIM B-1684. The strain CMIM B-1684 is described in the patent specification US-A-4,278,765.
The plasmid pYN7 was isolated from the strain VL334/pYN7. A
DNA fragment 6.25 kbp long which carries the thrABC operon was isolated from plasmid pYN7 by preparative agarose gel electrophoresis with the aid of the restriction enzymes
HindIII and BamHI.
The plasmid pBR322 (Bolivar et al., Gene 2, 95-113 (1977)) was obtained from Pharmacia Biotech (Uppsala, Sweden) and treated with the restriction enzymes HindIII and BamHI. The
DNA fragment 4.3 kbp long was isolated by preparative agarose gel electrophoresis. The two DNA fragments were mixed, treated with T4 DNA ligase, and the strain DHS5a was transformed with the ligation mixture. After selection on ampicillin-containing (50 pg/mL) LB agar, transformants which contained a plasmid which corresponded in its structure to the plasmid pYN7 were obtained.
The plasmid was isolated from a transformant, cleaved partly with the enzyme EcoRI and completely with the enzyme
HindIII and ligated with the parB gene region isolated. For this, the plasmid pKG1022 (Gerdes, Biotechnology (1988)
©:1402-1405) was cleaved with the enzymes EcoRI and
HindIII, the cleavage batch was separated in 1% agarose gel ) and the parB fragment 629 bp in size was isolated with the aid of the QIAquick Gel Extraction Kit (QIAGEN, Hilden,
Germany). The ligation mixture was employed for transformation of strain ATCC98082. Selection of plasmid- carrying cells was carried out on LB agar (Lennox, Virology 1:190 (1955)), to which 50 pg/ml ampicillin had been added.
Successful cloning of the parB gene region could be detected after isolation of the plasmid DNA, control cleavage with EcoRI and HindIII and analysis of the cleavage batch by agarose gel electrophoresis. The plasmid was designated pYN7parB.
A transformant of the type ATCC98082/pYN7parB has been designated DM1265 and deposited in the form of a pure culture on 30th April 1999 at the Deutsche Sammlung fur
Mikroorganismen und Zellkulturen (German Collection of
Microorganisms and Cell Cultures = DSM, Braunschweig,
Germany) as DSM12790 in accordance with the Budapest
Treaty.
The strain DM1265 has, inter alia, an enhanced, "feed back" resistant aspartate kinase I-homoserine dehydrogenase I, an attenuated threonine deaminase, a resistance to at least 5 g/l L-threonine and the ability to utilize sucrose as a source of carbon.
This strain is distinguished by a high stability, in particular segregation stability.
Comparative Example A
Preparation of L-threonine with the aid of the Escherichia coli K-12 strain DM1265 by conventional fermentation
An individual colony of the strain DM1265 was transinoculated on to minimal medium with the following composition: 3.5 g/1 Na HPO4*2H,0, 1.5 g/1 KH,PO4, 1 g/1
NH,C1l, 0.1 g/1 MgSO4*7H,0, 2 g/l sucrose, 20 g/l agar, : 50 mg/l ampicillin. The culture was incubated at 37°C for ’ approx. 5 days. 10 ml preculture medium with the following composition: 2 g/l yeast extract, 10 g/l (NH4)2S04, 1 g/1
KHPO4, 0.5 g/1 MgSO0,4*7H;0, 15 g/l CaCO;, 20 g/l sucrose, 50 mg/l ampicillin were inoculated with an inoculating loop and incubated for 16 (h) at 37°C and 180 rpm on an ESR incubator from Kihner AG (Birsfelden, Switzerland).
A volume of 1 ml of this first preculture was inoculated into 1402 g of the nutrient medium Al1-144. The culturing fermentation was carried out in 2 1 stirred reactor fermenters from B. Braun (BBI, Germany, Melsungen, Biostat
MD model). The nutrient medium Al1-144 contained the constituents listed in Table 1. This second preculture was cultured for 22.5 h at a temperature of 37°C, a volume- specific gassing of 0.71 vvm (volume per volume per minute), an oxygen partial pressure of 10% of the atmospheric saturation and a pH of pH 7.0 until an optical density (OD) (660 nm) of 16.3 was reached.
For inoculation of 1233 g of the growth medium M1-463, which was contained in 2 1 stirred reactor fermenters from
B. Braun (BBI, Germany, Melsungen, Biostat MD model), 157.6 g of the second preculture in nutrient medium Al1-144 were added. The growth medium M1-463 contained the constituents listed in Table 2. The culture was cultured at a temperature of 37°C, an aeration of 1 l/min, a minimum stirring of 800 rpm and a pH of 7.0 and an oxygen partial pressure of 20% of the atmospheric saturation until a residual sugar concentration of approx. 3 g/l was reached.
The broth obtained in this way was subsequently cultured for a further 30 h at a temperature of 37°C, an oxygen partial pressure of 20% of the atmospheric saturation and a pH of pH 7.0 until an OD (660 nm) of 33.4 was reached.
During this time, 450 g of a production medium comprising a
) sucrose solution with a concentration of 650 g/l was fed in continuously. :
The optical density (OD) was then determined with a- digital photometer of the LP1W type from Dr. Bruno Lange GmbH (Berlin, Germany) at a measurement wavelength of 660 nm and the concentration of L-threonine formed was determined by ion exchange chromatography and post-column reaction with ninhydrin detection with an amino acid analyzer from
Eppendorf~-BioTronik (Hamburg, Germany),
After 39.5 h, an L-threonine concentration of 69.6 g/l was found in the final fermentation sample. The space/time yield in this experiment was thus 1.76 g/1 - h.
Table 1
Composition of nutrient medium Al-144
EE EC
Table 2 : Composition of growth medium M1-463
Yeast extract 1.87 g
MgSQ4 - THO 0.38 ¢
Example 2 :
Preparation of L-threonine with the aid of the strain
DM1265 with 2 subsequent feed processes and 10% inoculum in each case
An individual colony of the strain DM1265 was transinoculated on to minimal medium with the following . 10 composition: 3.5 g/1 Na,HPO,*2H,0, 1.5 g/1 KH;PO4, 1 g/1
NH4.C1l, 0.1 g/1 MgSO,*7H,0, 2 g/l glucose, 20 g/l agar, : 50 mg/l ampicillin. The culture was incubated at 37°C for approx. 5 days. 10 ml preculture medium with the following composition: 2 g/l1 yeast extract, 10 g/l (NH4),SO,, 1 g/1
KHyPO4, 0.5 g/l MgSO,*7H,0, 15 g/1 CaCOs, 20 g/l glucose,
50 mg/l ampicillin were inoculated with an inoculating loop and incubated for 16 h at 37°C and 180 rpm on an ESR incubator from Kihner AG (Birsfelden, Switzerland). . A volume of 1 ml of this first preculture was inoculated into 1402 g of the nutrient medium Al1-144. The culturing fermentation was carried out in 2 1 stirred reactor fermenters from B. Braun (BBI, Germany, Melsungen, Biostat
MD model). The nutrient medium Al-144 contained the constituents listed in Table 1. This second preculture was cultured for 22.5 h at a temperature of 37°C, a volume- specific gassing of 0.71 vvm, an oxygen partial pressure of 10% of the atmospheric saturation and a pH of pH 7.0 until an OD (660 nm) of 16.3 was reached.
For inoculation of 1233 g of the growth medium M1-463, which was contained in 2 1 stirred reactor fermenters from
B. Braun (BBI, Germany, Melsungen, Biostat MD model), 157.6 g of the second preculture in nutrient medium Al-144 were added. The growth medium M1-463 contained the constituents listed in Table 2. The culture was cultured as described in Comparative Example A at a temperature of 37°C, an aeration of 1 l/min, a minimum stirring of 800 rpm and a pH of 7.0 and an oxygen partial pressure of 20% of the atmospheric saturation until a residual sugar concentration of approx. 3 g/l was reached after 9.5 h. The fermentation broth obtained in this way was then cultured for a further 30 h at a temperature of 37°C, an oxygen partial pressure of 20% of the atmospheric saturation and a pH of pH 7.0 until an OD (660 nm) of 33.4 was reached.
During this time, 450 g of a production medium comprising a sucrose solution with a concentration of 650 g/l was fed in continuously. After the feed solution had been consumed and the residual sugar in the fermentation broth of this first run had been consumed, 90% of the fermentation broth (1656 g) of the fermenter contents was removed by pumping off.
The remaining 10% of the volume (184 g) was topped up with 1200 g of the growth medium M1-474 and the fermentation was ’ started again. The growth medium M1-474 contained the constituents listed in Table 3. The culture of this second ) 5 run was cultured as described in Comparative Example A at a temperature of 37°C, an aeration of 1 l/min, a minimum stirring of 800 rpm and a pH of 7.0 and an oxygen partial pressure of 20% of the atmospheric saturation until a residual sugar concentration of approx. 3 g/l was reached after 5 h. The broth was then cultured for a further 31.25 h at a temperature of 37°C, an oxygen partial pressure of 20% of the atmospheric saturation and a pH of pH 7.0 until an OD (660 nm) of 35.7 was reached. During this time, 450 g of a production medium comprising a sucrose solution with a concentration of 650 g/l was fed in continuously. After the feed solution had been consumed and the residual sugar in the fermentation broth had been consumed, 90% of the fermentation broth (1656 g) was removed from the fermenter by pumping off.
The remaining 10% of the total amount (184 g) was topped up with 1200 g of the growth medium M1-474 and the fermentation was started again. The growth medium M1-474 contained the constituents listed in Table 3. The culture of this third run was cultured as described in Comparative
Example A at a temperature of 37°C, an aeration of 1 1/min, a minimum stirring of 800 rpm and a pH of 7.0 and an oxygen partial pressure of 20% of the atmospheric saturation until a residual sugar concentration of approx. 3 g/l was reached after 5.25 h. The culture was then cultured for a further 30.5 h at a temperature of 37°C, an oxygen partial pressure . of 20% of the atmospheric saturation and a pH of pH 7.0 until an OD (660 nm) of 32.5 was reached. During this time, 450 g of a production medium comprising a sucrose solution with a concentration of 650 g/1 was fed in.
At the end of each fermentation the OD and the concentration of L-threonine formed were determined as in
Comparative Example A. The results of the particular runs are shown in Table 4.
The term "space/time" yield here describes the volumetric productivity, i.e. the quotient of the concentration of L- threonine at the end of the fermentation and the fermentation time.
Table 3
Composition of growth medium M1-474
Yeast extract 1.68 g
MgSO, - 7H,0 0.38 g
Table 4
Results from Example 2
Run | Time [h] | L-Threonine OD Space/time (g/1] (660 yield nm) | [g/1 : hI
HEE EEE
Example 3
Preparation of L-threonine with the aid of the strain
DM1265 with 4 subsequent feed processes and 25% inoculation in each case
An individual colony of the strain DM1265 was transinoculated on to minimal medium with the following composition: 3.5 g/l Na,HPO4*2H,0, 1.5 g/l KH;PO4, 1 g/1
NH4C1l, 0.1 g/1 MgSO.*7H;0, 2 g/l glucose, 20 g/l agar, 50 mg/l ampicillin. The culture was incubated at 37°C for approx. 5 days. 10 ml preculture medium with the following composition: 2 g/l yeast extract, 10 g/1 (NH4).SO4, 1 g/l.
KHzPO4, 0.5 g/1 MgSO4*7H,0, 15 g/l CaCOs, 20 g/l glucose, 50 mg/l ampicillin were inoculated with an inoculating loop and incubated for 16 h at 37°C and 180 rpm on an ESR incubator from Kihner AG (Birsfelden, Switzerland).
A volume of 1 ml of this first preculture was inoculated into 1402 g of the nutrient medium Al-144. The culturing fermentation was carried out in 2 1 stirred reactor fermenters from B. Braun (BBI, Germany, Melsungen, Biostat
MD model). The nutrient medium Al-144 contained the constituents listed in Table 1. This second preculture was cultured for 22.5 h at a temperature of 37°C, a volume- specific gassing of 0.71 vvm, an oxygen partial pressure of il 10% of the atmospheric saturation and a pH of pH 7.0 until an OD (660 nm) of 16.3 was reached. 5S For inoculation of 1233 g of the growth medium M1-463, which was contained in 2 1 stirred reactor fermenters from
B. Braun (BBI, Germany, Melsungen, Biostat MD model), 157.6 g of the second preculture in nutrient medium Al-144 were added. The growth medium M1-463 contained the constituents listed in Table 2. The culture was cultured as described in Comparative Example A at a temperature of 37°C, an aeration of 1 1/min, a minimum stirring of 800 rpm and a pH of 7.0 and an oxygen partial pressure of 20% of the atmospheric saturation until a residual sugar concentration of approx. 3 g/l was reached after 9.5 h. The fermentation broth obtained in this way was then cultured for a further 32 h at a temperature of 37°C, an oxygen partial pressure of 20% of the atmospheric saturation and a pH of pH 7.0 until an OD (660 nm) of 35.8 was reached.
During this time, 450 g of a production medium comprising a sucrose solution with a concentration of 650 g/l was fed in continuously. After the feed solution had been consumed and the residual sugar in the fermentation broth of this first run had been consumed, 75% of the fermentation broth of the fermenter contents was removed by pumping off. The first fermentation (first run) was ended after 41.5 h and reached a titre of 67.1 g/l threonine.
The remaining 25% of the total amount (453 g) was topped up with 700 g of the growth medium M1-527 and the fermentation was started again. The growth medium M1-527 contained the constituents listed in Table 5. The culture of this second run was cultured as described in Comparative Example A at a temperature of 37°C, an aeration of 1 1/min, a minimum stirring of 800 rpm and a pH of 7.0 and an oxygen partial pressure of 20% of the atmospheric saturation until a
~ residual sugar concentration of approx. 3 g/l was reached.
The culture was then cultured for a further 30 h at a ) temperature of 37°C, an oxygen partial pressure of 20% of the atmospheric saturation and a pH of pH 7.0 until an OD ) 5 (660 nm) of 36.2 was reached. During this time, 450 g of a production medium comprising a sucrose solution with a concentration of 650 g/l was fed in as in the first run.
The draining off of the fermentation broth to 25% and the topping up of the fermenter with M1-527 was repeated a total of four times.
At the end of each fermentation the OD and the concentration of L-threonine formed were determined as in
Comparative Example A.
Table 6 shows the results of the particular runs. The term "Total L-threonine formed" relates to the L-threonine effectively formed or produced during the fermentation run.
To calculate the total L-threonine formed, the amount of L- threonine introduced by the inoculum is subtracted from the amount of L-threonine present in the fermentation tank at the end of the run. The term "Productivity" designates the quotient of the total L-threonine formed per fermentation run and the fermentation time per run.
Table 5 : Composition of growth medium M1-527
EL I
Table 6 . Results from Example 3
Run Time [h] | L-Threonine OD Total L- Product- [g/1] (660 Threonine ivity nm) formed [g/h] lg]
IE CE
Comparative Example B
S Preparation of L-threonine with the aid of the Escherichia coli K-12 strain kat-13 by conventional fermentation
The L-threonine-producing E. coli strain kat-13 is described in US-A-5,939,307 and deposited at the
Agriculture Research Service Patent Culture Collection (Peoria, Illinois, USA) as NRRL B-21593.
The strain kat-13 has, inter alia, an enhanced, "feed back" resistant aspartate kinase I-homoserine dehydrogenase I, an attenuated threonine dehydrogenase, resistance to borrelidin and the ability to utilize sucrose as a source of carbon.
An individual colony of the strain kat-13 was transinoculated on to minimal medium with the following composition: 3.5 g/1 NapHPO4*2H,0, 1.5 g/l KHzPO,, 1 g/1
NH4Cl, 0.1 g/1 MgS0,*7H,0, 2 g/l glucose, 20 g/l agar. The culture was incubated at 37°C for approx. 5 days. 10 ml preculture medium with the following composition: 2 g/l
Cl yeast extract, 10 g/l (NH4)2S04, 1 g/l KHPO,, 0.5 g/1
MgSO4*7H,0, 15 g/l CaCOs, 20 g/1 glucose, were inoculated with an inoculating loop and incubated for 16 h at 37°C and 180 rpm on an ESR incubator from Kiihner AG (Birsfelden,
Switzerland).
A volume of 0.45 ml of this first preculture was inoculated into 1500 g of the nutrient medium Al1-158. The culturing fermentation was carried out in 2 1 stirred reactor fermenters from B. Braun (BBI, Germany, Melsungen, Biostat
MD model). The nutrient medium A1-158 contained the constituents listed in Table 7. This second preculture was cultured for 19.75 h at a volume-specific gassing of 1.16 vvm, an oxygen partial pressure of 20% of the atmospheric saturation and a pH of pH 6.9 until all the glucose had been consumed. The fermentation was started at a temperature of 39°C, and after a fermentation time of 18 h the temperature was lowered to 37°C.
For inoculation of 725 g of the growth medium M1-530, which was contained in 2 1 stirred reactor fermenters from B.
Braun (BBI, Germany, Melsungen, Biostat MD model), 110 g of the second preculture in nutrient medium Al1-158 were added.
The growth medium M1-530 contained the constituents listed in Table 8. The culture was cultured at a temperature of 37°C, an aeration of 1.3 1/min, a minimum stirring of 800 rpm and a pH of 7.0 and an oxygen partial pressure of 20% of the atmospheric saturation until all the glucose initially introduced had been consumed after 8 h. The fermentation broth obtained in this way was then cultured for a further 57 h at a temperature of 37°C, an oxygen partial pressure of 20% of the atmospheric saturation, an aeration of 1.5 1/min and a pH of pH 7.0. During this time, 1000 g of a production medium comprising a glucose-+H,0
° 23 solution with a concentration of 550 g/1 was fed in continuously.
The OD and the concentration of L-threonine formed were . then determined as in Comparative Example A.
S After 65 h, an L-threonine concentration of 101.3 g/l was found in the final fermentation sample. The space/time yield in this experiment was thus 1.56 g/l - h.
Table 7
Composition of nutrient medium Al-158
Table 8 : : Composition of growth medium M1-530
Example 4
Preparation of L-threonine with the aid of the strain kat- 13 with a subsequent feed process and 10% inoculation
An individual colony of the strain kat-13 was transinoculated on to minimal medium with the following composition: 3.5 g/l Na;HPO4*2H,0, 1.5 g/l KH;PO,, 1 g/l : 10 NH, Cl, 0.1 g/l MgSOs*7H20, 2 g/1 glucose, 20 g/l agar. The culture was incubated at 37°C for approx. 5 days. 10 ml preculture medium with the following composition: 2 g/1 yeast extract, 10 g/l (NH4)2S0,, 1 g/1 KH,PO4, 0.5 g/1
MgS04*7H,0, 15 g/1 CaCOsz, 20 g/l glucose, were inoculated with an inoculating loop and incubated for 16 h at 37°C and
180 rpm on an ESR incubator from Kiihner AG (Birsfelden,
Switzerland).
A volume of 0.45 ml of this first preculture was inoculated . into 1500 g of the nutrient medium A1-158. The culturing fermentation was carried out in 2 1 stirred reactor fermenters from B. Braun (BBI, Germany, Melsungen, Biostat
MD model). The nutrient medium A1-158 contained the constituents listed in Table 7. This second preculture was cultured for 19.75 h at a volume-specific gassing of 1.16 vvm, an oxygen partial pressure of 20% of the atmospheric saturation and a pH of pH 6.9 until all the glucose had been consumed. The fermentation was started at a temperature of 39°C, and after a fermentation time of 18 h the temperature was lowered to 37°C.
For inoculation of 725 g of the growth medium M1-530, which was contained in 2 1 stirred reactor fermenters from B.
Braun (BBI, Germany, Melsungen, Biostat MD model), 110 g of the second preculture in nutrient medium A1-158 were added.
The growth medium M1-530 contained the constituents listed in Table 8. The culture was cultured at a temperature of 37°C, an aeration of 1.3 1/min, a minimum stirring of 800 rpm and a pH of 7.0 and an oxygen partial pressure of 20% of the atmospheric saturation until all the glucose initially introduced had been consumed after 8 h. The fermentation broth obtained in this way was then cultured for a further 57 h at a temperature of 37°C, an oxygen partial pressure of 20% of the atmospheric saturation, an aeration of 1.5 1/min and a pH of pH 7.0 until an OD (660 nm) of 46.4 was reached. During this time, 1000 g of a production medium comprising a glucose-H,O solution with a concentration of 550 g/1 was fed in continuously. After the feed solution had been consumed and the residual sugar in the fermentation broth of this first run had been consumed, 90% of the fermentation broth (1651 g) of the fermenter contents was removed by pumping off.
The remaining 10% of the volume (184 g) was topped up with 650 g of the growth medium M1-531 and the fermentation was started again. The growth medium M1-531 contained the constituents listed in Table 9. The culture was cultured at a temperature of 37°C, an aeration of 1.5 1/min, a minimum stirring of 800 rpm and a pH of 7.0 and an oxygen partial pressure of 20% of the atmospheric saturation. During this _ time, 1000 g of a production medium comprising a glucose-H,0 solution with a concentration of 550 g/1 was fed in continuously.
At the end of each fermentation the OD and the : concentration of L-threonine formed were determined as in
Comparative Example A.
The results of the two runs are shown in Table 10. The term "Total L-threonine formed" relates to the L-threonine effectively formed or produced during the fermentation run.
To calculate the total L-threonine formed, the amount of L- threonine introduced by the inoculum is subtracted from the amount of L-threonine present in the fermentation tank at the end of the run. The term "Productivity" designates the quotient of the total L-threonine formed per fermentation run and the fermentation time per run.
Table 9 : Composition of growth medium M1-531
Table 10 5S Results of Example 4
Run | Time [h] | L-Threonine OD total L- Product- {g/1] (660 Threonine ivity nm) formed [g/h]
CTE EEE ree [oro Jue] ae | ose 2 [ee | ene [eo] wre | oem
’ | 28
Comparative Example C ~ Preparation of L-threonine with the aid of the Escherichia coli K-12 strain B-3996 by conventional fermentation
The L-threonine-producing E. coli strain B-3996 is described in US-A-5,175,107 and deposited at the Russian
National Collection for Industrial Microorganisms (VKPM,
Moscow, Russia).
The strain B-3996 has, inter alia, an enhanced, "feed back" resistant aspartate kinase I-homoserine dehydrogenase I, an attenuated threonine deaminase, an attenuated threonine dehydrogenase, a resistance to at least 5 g/l L-threonine and the ability to utilize sucrose as a source of carbon.
An individual colony of the strain B-3996 was transinoculated on to minimal medium with the following composition: 3.5 g/l NayHPO,*2H,0, 1.5 g/l KH,PO4, 1 g/1
NHsCl, 0.1 g/1 MgSO4*7H;0, 2 g/l sucrose, 20 g/l agar, pg/ml streptomycin. The culture was incubated at 37°C for approx. 5 days. 10 ml preculture medium with the following composition: 2 g/l yeast extract, 10 g/l 20 (NH4)2S04, 1 g/1 KHpPO,, 0.5 g/1 MgSO,*7H,0, 15 g/l CaCOs, 20 g/1 sucrose, 20 pg/ml streptomycin were inoculated with an inoculating loop and incubated for 16 h at 37°C and 180 rpm on an ESR incubator from Kiihner AG (Birsfelden,
Switzerland).
A volume of 20 ml of this first preculture was inoculated into 1000 g of the nutrient medium Al1-160. The culturing fermentation was carried out in 2 1 stirred reactor fermenters from B. Braun (BBI, Germany, Melsungen, Biostat
MD model). The nutrient medium A1-160 contained the constituents listed in Table 11. This second preculture was cultured for 14 h at a temperature of 37°C, a volume- specific gassing of 1.00 vvm, an oxygen partial pressure of
10% of the atmospheric saturation and a pH of pH 6.9 until all the sucrose had been consumed.
For inoculation of 1000 g of the growth medium M1-546, . which was contained in 2 1 stirred reactor fermenters from 5S B. Braun (BBI, Germany, Melsungen, Biostat MD model), 100 g of the second preculture in nutrient medium Al1-160 were added. The growth medium M1-546 contained the constituents listed in Table 12. The culture was cultured at a temperature of 37°C, an aeration of 1.0 l/min, a minimum stirring of 800 rpm and a pH of 6.9 and an oxygen partial pressure of 20% of the atmospheric saturation until all the sucrose initially introduced had been consumed after 7 h.
The fermentation broth obtained in this way was then cultured for a further 29 h at a temperature of 37°C, an oxygen partial pressure of 20% of the atmospheric saturation, an aeration of 1.0 1/min and a pH of pH 6.9.
During this time, a production medium comprising a sucrose solution with a concentration of 600 g/kg was fed in such that the sucrose concentration was always above 0.5 g/l.
The optical density (OD) was then determined with a digital photometer of the LPIW type from Dr. Bruno Lange GmbH (Berlin, Germany) at a measurement wavelength of 660 nm and the concentration of L-threonine formed was determined by ion exchange chromatography and post-column reaction with ninhydrin detection with an amino acid analyzer from
Eppendorf-BioTronik (Hamburg, Germany), 63.8 g L-threonine were produced in the fermentation in 36 h. The productivity in this experiment was thus 1.77 g/h.
co 30
Table 11 : . Composition of nutrient medium —
EE RC
EE IC
EE ECR i 31
Table 12 } Composition of growth medium M1-546
Ea ICR
Example 5
Preparation according to the invention of L-threonine with the aid of the Escherichia coli K-12 strain B-3996 with 5 subsequent feed processes and 10% inoculation in each case
For inoculation of 1000 g of the growth medium M1-546, which was contained in 2 1 stirred reactor fermenters from
B. Braun (BBI, Germany, Melsungen, Biostat MD model), 100 g of the second preculture in nutrient medium A1l-160 were : added, as described in Example 7. The growth medium M1-546 contained the constituents listed in Table 12. The culture : was cultured at a temperature of 37°C, an aeration of 1.0 1/min, a minimum stirring of 800 rpm and a pH of 6.9 and an oxygen partial pressure of 20% of the atmospheric . saturation until all the sucrose initially introduced had been consumed after 7 h. The fermentation brotH obtained in this way was then cultured for a further 29 h at a temperature of 37°C, an oxygen partial pressure of 20% of the atmospheric saturation, an aeration of 1.0 l/min and a ) 5 pH of pH 6.9. During this time, 411.8 g of a production medium comprising a sucrose solution with a concentration of 600 g/kg was fed in continuously.
The fermentation broth was then drained off to 10% of the total amount. The remaining 10% of the total amount was topped up with growth medium M1-546 to the starting weight of 1100 g and the fermentation was started again. The growth medium M1-546 contained the constituents listed in
Table 13. The culture of this third run was cultured as described in Example 7 at a temperature of 37°C, an aeration of 1 1/min, a minimum stirring of 800 rpm and a pH of 6.9 and an oxygen partial pressure of 20% of the atmospheric saturation until all the sucrose initially introduced had been consumed after 8 h. The culture was then cultured for a further 28 h at a temperature of 37°C, an oxygen partial pressure of 20% of the atmospheric saturation and a pH of pH 6.9. During this time, a . production medium comprising a sucrose solution with a concentration of 600 g/kg was fed in such that the sucrose concentration in the fermenter was always above 0.5 g/l.
After a total of 36 h, the fermentation run was ended. The draining off of the fermentation broth to 10% and the topping up of the fermenter with M1-546 was repeated a total of five times.
At the end of each fermentation the OD and the concentration of L-threonine formed were determined as in
Comparative Example A. ‘ Table 13 shows the results of the particular runs. The term "Total L-threonine formed" relates to the L-threonine effectively formed or produced during the fermentation run.
To calculate the total L-threonine formed, the amount of L-
threonine introduced by the inoculum is subtracted from the amount of L-threonine present in the fermentation tank at . the end of the run. The term "Productivity" designates the quotient of the total L-threonine formed per fermentation
S 5 run and the fermentation time per run.
Table 13:
Results of Example 5
Run Time [h] | L-Threonine ~ OD Total L- Product- : yield (660 | Threonine ivity (g/g nm) formed [g/h] sucrose] (g]
IE I 2 I 1 I IN KC) a
IE EC NC Ca CO NC
L IDENTIFICATION OF THE MICROORGANISM
Identification reference given by the DEPOSITOR: Accession number given by the
INTERNATIONAL DEPOSITARY AUTHORITY:
DM1265
DSM 12790
The microorganism identified under 1. above was accompanied by: (3) a scientific description - CC ’ (X) a proposed taxonomic designation (Mark with a cross where applicable).
This International Depositary Authority accepts the microorganism identified under 1. above, which was received by ton 1999-04-29 (Date of the original deposit)’.
IV. RECEIPT OF REQUEST FOR CONVERSION
The microorganism identified under | above was received by this Intemational Depositary Authority on (date of original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by iton (date of receipt of request for conversion).
V. INTERNATIONAL DEPOSITARY AUTHORITY h Name: DSMZ-DEUTSCHE SAMMLUNG VON Signature(s) of person(s) having the power to represent the
MIKROORGANISMEN UND ZELLKULTUREN GmbH Intemational Depositary Authority or of authorized official(s):
Address: Mascheroder Weg 1b -
D-38124 Braunschweig ) Co Ae
Date: 1999-04-30 ' Where Rule 6.4 (d) applies, such date is the date on which the status of international depositary suthority was acquired.
Form DSMZ-BP/4 (soc page) 0196
1. DEPOSITOR 11. IDENTIFICATION OF THE MICROORGANISM
Name: Degussa-Huls AG . Accession number given by the
Kantstr. 2 INTERNATIONAL DEPOSITARY AUTHORITY:
Address: DSM 12790 33790 Halle i.W.
Date of the deposit or the transfer’: 1899-04-29
Jil. VIABILITY STATEMENT
The viability of the microorganism identified under 11 above was testedon 1999-04-29 2.
On that date, the said microorganism was (X)* viable : ( ) no longer viable
IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED'
V. INTERNATIONAL DEPOSITARY AUTHORITY ’
Name: DSMZ-DEUTSCHE SAMMLUNG VON Signature(s) of person(s) having the power to represent the
MIKROORGANISMEN UND ZELLKULTUREN GmbH International Depositary Authority or of authorized official(s):
Address: Mascheroder Weg 1b 4 (/ - 4 3 D-38124 Braunschweig Ps yr
Dae: 1999-04-30 ! Indicate the date of original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer). h In the cases referred to in Rule 10.2(2) (ii) and (iii), refer to the most recent viability test. > Mark with a cross the applicable box. ‘ Fill in if the information has been requested and if the results of the test were negative,
Form DSMZ-BP/ (sole page) 0196
Claims (12)
- What is claimed is: . 1. Process for the fermentative preparation of L- threonine, wherein AS a) an L-threonine-producing microorganism of the Enterobacteriaceae family is cultured by the feed process (fed batch), subsequently b) a portion of the fermentation broth is separated off, 1 to 90 vol.%, in particular 1 to 50 vol.$, preferably 1 to 25 vol.% of the total volume of the fermentation broth remaining in the fermentation tank, subsequently c) the remaining fermentation broth is topped up with growth medium and, preferably after a growth phase, a further fermentation is carried out in accordance with a), d) steps b) and c) are optionally carried out several times, and e) the L-threonine is isolated from the fermentation broths collected.
- 2. Process according to claim 1, wherein steps b) and c) are carried out two to six times and the L-threonine is isolated from the fermentation broths collected.
- 3. Process according to claims 1 and 2, wherein . microorganisms of the species Escherichia coli are employed. :
- ’ 4. L-Threonine-producing and -secreting microorganisms of the Entercbacteriaceae family which have an enhanced ‘ resistant aspartate kinase I-homoserine dehydrogenase I, an attenuated threonine deaminase, a resistance to at least 5 g/l threonine and the ability to utilize he 37 sucrose as a source of carbon, and the parB gene region.
- 5. Transformants according to claim 4, deposited under © number DSM 12790 at the DSMZ [German Collection of Microorganisms and Cell Cultures], Braunschweig.
- 6. Process according to claims 1 and 2, wherein L- threonine-producing and -secreting microorganisms of the Enterobacteriaceae family which have one or more of the features chosen from the group consisting of: an -10 enhanced, feed back resistant aspartate kinase I- homoserine dehydrogenase I, an attenuated threonine deaminase, an attenuated threonine dehydrogenase, a resistance to at least 5 g/l threonine, a resistance to borrelidin, a resistance to a-methylserine, a resistance to diaminosuccinic acid, a sensitivity to fluoropyruvate, a resistance to L-glutamic acid, a need for L-methionine, and the ability to utilize sucrose as a source of carbon are used.
- 7. Process according to claim 6, wherein L-threonine- producing and ~secreting microorganisms of the Enterobacteriaceae family which have an enhanced resistant aspartate kinase I-homoserine dehydrogenase I, an attenuated threonine deaminase, a resistance to : at least 5 g/l threonine and the ability to utilize sucrose as a source of carbon are used.
- 8. Process according to claims 1 and 2, wherein L- threonine-producing and -secreting microorganisms of the Enterobacteriaceae family which have one or more of ; the features chosen from the group consisting of: an enhanced, feed back resistant aspartate kinase I-. homoserine dehydrogenase I, an attenuated threonine deaminase, an attenuated threonine dehydrogenase, a resistance to at least 5 g/l threonine and the ability to utilize sucrose as a source of carbon are used.
- 9. Process according to claims 1 and 2, wherein L- threonine-producing and -secreting microorganisms of ’ the Enterobacteriaceae family which have one or more of the features chosen from the group consisting of: an v 5 enhanced, feed back resistant aspartate kinase I- homoserine dehydrogenase I, an attenuated threonine deaminase, a resistance to borrelidin and the ability to utilize sucrose as a source of carbon are used.
- 10. Process according to claims 1 and 2, wherein L- threonine-producing and -secreting microorganisms of the Enterobacteriaceae family which have one or more of the features chosen from the group consisting of: a resistance to a-methylserine, a resistance to diaminosuccinic acid, a sensitivity to fluoropyruvate, a resistance to L-glutamic acid and a resistance to at least 7% L-threonine, a need for L-methionine and a need for L-isoleucine are used.
- 11. Process according to claims 1 and 2, wherein L- threonine-producing and -secreting microorganisms of “the Enterobacteriaceae family which have one or more of the features or characteristics of the strains chosen from the group consisting of: DSM12790, B-3996, kat 13, KCCM-1032 and KCCM~1033 are used.
- 12. Process according to claims 1 and 2, wherein one or more strains chosen from the group consisting of DSM12790, B-3996, kat 13, KCCM-1032 and KCCM-1033 are used. *
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10042745 | 2000-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200301636B true ZA200301636B (en) | 2004-02-03 |
Family
ID=7654405
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200301636A ZA200301636B (en) | 2000-08-31 | 2003-02-27 | Fermentation process for the preparation of L-threonine. |
Country Status (3)
Country | Link |
---|---|
KR (1) | KR20030033039A (en) |
DE (1) | DE10103778A1 (en) |
ZA (1) | ZA200301636B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005014840A1 (en) * | 2003-08-01 | 2005-02-17 | Degussa Ag | Process for the preparation of l-threonine |
WO2005014842A1 (en) * | 2003-08-01 | 2005-02-17 | Degussa Ag | Process for the preparation of l-threonine |
WO2005021773A1 (en) * | 2003-08-29 | 2005-03-10 | Degussa Ag | Process for the preparation of l-lysine |
-
2001
- 2001-01-27 DE DE10103778A patent/DE10103778A1/en not_active Withdrawn
- 2001-07-25 KR KR10-2003-7002959A patent/KR20030033039A/en not_active Application Discontinuation
-
2003
- 2003-02-27 ZA ZA200301636A patent/ZA200301636B/en unknown
Also Published As
Publication number | Publication date |
---|---|
DE10103778A1 (en) | 2002-03-14 |
KR20030033039A (en) | 2003-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100838038B1 (en) | - - a microorganism of corynebacterium genus having enhanced l-lysine productivity and a method of producing l-lysine using the same | |
EP1320626B1 (en) | Fermentation process for the preparation of l-amino acids using strains of the family enterobacteriaceae | |
KR100838035B1 (en) | - - a microorganism of corynebacterium genus having enhanced l-lysine productivity and a method of producing l-lysine using the same | |
EP1217076B1 (en) | Method of producing a target substance by fermentation | |
KR101592140B1 (en) | Corynebacterium sp. having xylose availability and process for preparing L-lysine employing the same | |
EP1330526B1 (en) | Process for the fermentative preparation of l-amino acids using strains of the enterobacteriaceae family | |
CN1128295A (en) | Method of producing L-glutamic acid by fermentation | |
EP1285075B1 (en) | Process for the fermentative preparation of l-threonine | |
EP1313838A2 (en) | Fermentation process for the preparation of l-threonine | |
US6916637B2 (en) | Fermentation process for the preparation of L-amino acids using strains of the family Enterobacteriaceae | |
KR100837844B1 (en) | - - Microoragnism of Corynbacterium genus with an enhanced L-glutamic acid productivity and method of producing L-glutamic acid using the microorganism | |
EP1654376A2 (en) | A process for preparing l-threonine | |
WO2005014841A1 (en) | Process for the preparation of l-threonine | |
EP1649033A1 (en) | Process for the preparation of l-threonine | |
EP0204326A2 (en) | Process for producing L-threonine and L-isoleucine | |
EP1929028A1 (en) | An l-amino acid-producing bacterium and a method for producing l-amino acids | |
US6562601B2 (en) | Fermentation process for the preparation of L-threonine | |
KR20000013852A (en) | Preparation method of l-threonine from e.coli dsm 9806(kccm-10133) | |
ZA200301636B (en) | Fermentation process for the preparation of L-threonine. | |
EP1002866A1 (en) | TEMPERATURE SENSITIVE dtsR GENES | |
US20030190712A1 (en) | Fermentation process for the preparation of L-threonine | |
Masuda et al. | Improvement of culture conditions for L-proline production by a recombinant strain of Serratia marcescens | |
US20030017554A1 (en) | Process for the fermentative preparation of L-amino acids using strains of the enterobacteriaceae family | |
EP3677594A1 (en) | Method for producing l-tryptophan using improved strains of the enterobacteriaceae family | |
US20060252133A1 (en) | Process for the preparation of l-threonine |